Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

NCT03245151 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03245151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03245151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 16, 2017
Completion date
September 30, 2022
Enrollment
64 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent and refractory solid tumors